Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Code Blending By CMS Could Cause Tracking, Payment Problems

This article was originally published in The Pink Sheet Daily

Executive Summary

Rivals Sandoz and Amgen both say CMS decision on J-codes removes feature for tracking adverse events.

You may also be interested in...



Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming

Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.

US FDA Oncology, Device Centers Developing Public Diagnostic Standards

Pilot program would get around the ‘one drug, one test’ policy, which has created intellectual property issues.

AAM CEO Leonard Departs After Two Years, Creating Another Trade Group Searching For New Leader

David Gaugh, AAM’s executive VP of sciences and regulatory affairs, was named the interim CEO, making him the fourth person to run the association since February 2020.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel